The outcome of rituximab in treating steroid dependent nephrotic syndrome.: Histopathology and immunosuppressive drugs as predicting factors.

Autor:	Al Salloum AA; From the Department of Pediatrics (Al Salloum, Al Herbish, Al Hissi, Abdallah, Salim, Farhat, Shagal, Othman, Alshiban, Temsah, Al-Eyadhy, Alhasan), College of Medicine, King Saud University, King Saud University Medical City, and from the Department of Pediatric Kidney Transplant (Alhasan), Organ Transplant Center of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh, Kingdom of Saudi Arabia., Al Herbish AJ; From the Department of Pediatrics (Al Salloum, Al Herbish, Al Hissi, Abdallah, Salim, Farhat, Shagal, Othman, Alshiban, Temsah, Al-Eyadhy, Alhasan), College of Medicine, King Saud University, King Saud University Medical City, and from the Department of Pediatric Kidney Transplant (Alhasan), Organ Transplant Center of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh, Kingdom of Saudi Arabia., Al Hissi MA; From the Department of Pediatrics (Al Salloum, Al Herbish, Al Hissi, Abdallah, Salim, Farhat, Shagal, Othman, Alshiban, Temsah, Al-Eyadhy, Alhasan), College of Medicine, King Saud University, King Saud University Medical City, and from the Department of Pediatric Kidney Transplant (Alhasan), Organ Transplant Center of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh, Kingdom of Saudi Arabia., Abdalla MS; From the Department of Pediatrics (Al Salloum, Al Herbish, Al Hissi, Abdallah, Salim, Farhat, Shagal, Othman, Alshiban, Temsah, Al-Eyadhy, Alhasan), College of Medicine, King Saud University, King Saud University Medical City, and from the Department of Pediatric Kidney Transplant (Alhasan), Organ Transplant Center of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh, Kingdom of Saudi Arabia., Salim SB; From the Department of Pediatrics (Al Salloum, Al Herbish, Al Hissi, Abdallah, Salim, Farhat, Shagal, Othman, Alshiban, Temsah, Al-Eyadhy, Alhasan), College of Medicine, King Saud University, King Saud University Medical City, and from the Department of Pediatric Kidney Transplant (Alhasan), Organ Transplant Center of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh, Kingdom of Saudi Arabia., Farhat AH; From the Department of Pediatrics (Al Salloum, Al Herbish, Al Hissi, Abdallah, Salim, Farhat, Shagal, Othman, Alshiban, Temsah, Al-Eyadhy, Alhasan), College of Medicine, King Saud University, King Saud University Medical City, and from the Department of Pediatric Kidney Transplant (Alhasan), Organ Transplant Center of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh, Kingdom of Saudi Arabia., Shagal RA; From the Department of Pediatrics (Al Salloum, Al Herbish, Al Hissi, Abdallah, Salim, Farhat, Shagal, Othman, Alshiban, Temsah, Al-Eyadhy, Alhasan), College of Medicine, King Saud University, King Saud University Medical City, and from the Department of Pediatric Kidney Transplant (Alhasan), Organ Transplant Center of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh, Kingdom of Saudi Arabia., Othman A; From the Department of Pediatrics (Al Salloum, Al Herbish, Al Hissi, Abdallah, Salim, Farhat, Shagal, Othman, Alshiban, Temsah, Al-Eyadhy, Alhasan), College of Medicine, King Saud University, King Saud University Medical City, and from the Department of Pediatric Kidney Transplant (Alhasan), Organ Transplant Center of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh, Kingdom of Saudi Arabia., Alshaiban A; From the Department of Pediatrics (Al Salloum, Al Herbish, Al Hissi, Abdallah, Salim, Farhat, Shagal, Othman, Alshiban, Temsah, Al-Eyadhy, Alhasan), College of Medicine, King Saud University, King Saud University Medical City, and from the Department of Pediatric Kidney Transplant (Alhasan), Organ Transplant Center of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh, Kingdom of Saudi Arabia., Temsah MA; From the Department of Pediatrics (Al Salloum, Al Herbish, Al Hissi, Abdallah, Salim, Farhat, Shagal, Othman, Alshiban, Temsah, Al-Eyadhy, Alhasan), College of Medicine, King Saud University, King Saud University Medical City, and from the Department of Pediatric Kidney Transplant (Alhasan), Organ Transplant Center of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh, Kingdom of Saudi Arabia., Al-Eyadhy AA; From the Department of Pediatrics (Al Salloum, Al Herbish, Al Hissi, Abdallah, Salim, Farhat, Shagal, Othman, Alshiban, Temsah, Al-Eyadhy, Alhasan), College of Medicine, King Saud University, King Saud University Medical City, and from the Department of Pediatric Kidney Transplant (Alhasan), Organ Transplant Center of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh, Kingdom of Saudi Arabia., Alhasan KA; From the Department of Pediatrics (Al Salloum, Al Herbish, Al Hissi, Abdallah, Salim, Farhat, Shagal, Othman, Alshiban, Temsah, Al-Eyadhy, Alhasan), College of Medicine, King Saud University, King Saud University Medical City, and from the Department of Pediatric Kidney Transplant (Alhasan), Organ Transplant Center of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh, Kingdom of Saudi Arabia.
Jazyk:	angličtina
Zdroj:	Saudi medical journal [Saudi Med J] 2022 Jul; Vol. 43 (7), pp. 760-764.
DOI:	10.15537/smj.2022.43.7.20210727
Abstrakt:	Objectives: To present our experience of treating steroid-dependent nephrotic syndrome (SDNS) in children with repeated doses of rituximab (RTX) with a relatively long follow-up, and to discuss the role of the histopathology type and previous immune-suppressor (IS) drugs on the outcome of these patients. Methods: The patients included in this prospective study were children with SDNS who were in remission on a high-dose steroid or with additional IS drugs. All patients underwent renal biopsy before RTX treatment. Intravenous RTX was administered monthly at 375 mg/m 2 for 4 doses. Response to treatment was defined as maintaining remission with no steroid-sparing agents or prednisone for one year. Results: Seventeen (14 males) patients were enrolled. Approximately 76% had minimal change disease (MCD) and 3 (18%) patients had immunoglobulin M (IgM) nephropathy. Approximately 85% of MCD and 33% of IgM nephropathy showed complete response to RTX. Conclusion: Compared to other IS used to treat SDNS, RTX showed a significant decrease in relapse rate with fewer side effects. The dose and interval should be modified according to the patient's characteristics, such as medical history, pathology type, and previous IS agents. (Copyright: © Saudi Medical Journal.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu